Catch up on what happened in optometry during the week of December 11-December 15.
Catch up with what Optometry Times® shared this week:
David Hutton, Managing Editor, Ophthalmology Times
iDose TR, a micro-invasive intraocular implant designed to lower IOP in patients with open-angle glaucoma or ocular hypertension, has received FDA approval following a new drug application (NDA) submission.
Emily Kaiser Maharjan, Assistant Managing Editor
A research report compiled by The Vision Council reveals that most parents are aware of myopia but remain in the dark about prevalence and how to prevent progression.
Kyra Dorgeloh, OD, FAAO; Leena Walker, OD, FAAO
Hydroxychloroquine is considered to have a favorable systemic safety profile, even for long-term use, but poses the risk for retinal toxicity and irreversible vision loss.
Martin David Harp, Associate Editor, Ophthalmology Times
TP-03 (lotilaner ophthalmic solution, 0.25%) was approved by the FDA in 2023 under the brand name Xdemvy for the treatment of Demodex blepharitis and is being evaluated as an investigational therapy for the treatment of Meibomian Gland Disease (MGD) in patients with Demodex mites.
Martin David Harp, Associate Editor, Ophthalmology Times; Emily Kaiser Maharjan, Assistant Managing Editor
Eye care witnessed a transformative year with 11 FDA approvals. As the year concludes, there remains a robust pipeline of drugs, setting high expectations for continued advancements in ophthalmological care in 2024 and beyond.